<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077670</url>
  </required_header>
  <id_info>
    <org_study_id>Hybrid-AFMAP</org_study_id>
    <nct_id>NCT05077670</nct_id>
  </id_info>
  <brief_title>Hybrid Characterization of Driver Sites During Atrial Fibrillation and Sinus Rhythm</brief_title>
  <acronym>Hybrid-AFMAP</acronym>
  <official_title>Hybrid Characterization of Driver Sites During Atrial Fibrillation and Sinus Rhythm With CARTOFINDER and COHERENT Mapping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Innovacion en Biomedicina (FIBMED)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion para la Innovacion en Biomedicina (FIBMED)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is twofold, first we aim to identify rotors in atrial&#xD;
      fibrillation (AF) and analyze their relationship with the left atrium-left atrial appendage&#xD;
      (LA-LAA) connections. Secondly, we will analyze the areas harboring rotors in SR to define&#xD;
      the characteristics that describe the presence of rotors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is the identification of LA and LAA areas driving atrial&#xD;
      fibrillation to study their relationship with LAA-LA connections and sinus rhythm (SR)&#xD;
      analysis using the CartoFinder and COHERENT algorithms that CARTO V7 offers.&#xD;
&#xD;
      The CartoFinder tool will be able to determine the activation patterns of reentrant drivers&#xD;
      (rotors) in the LA and LAA in AF. The characterization of areas harboring rotors could be&#xD;
      performed with the COHERENT tool provided by CARTO V7 to determine the activation patterns&#xD;
      during reentrant rhythms, and after sinus rhythm restoration it could be used to assess the&#xD;
      conduction patterns at LA-LAA connections and driver sites identified with CartoFinder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>CartoFinder and COHERENT tools utility assessment</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the utility of CartoFinder and COHERENT tools in the identification of the mechanisms that maintain atrial fibrillation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation driver location analysis</measure>
    <time_frame>2 years</time_frame>
    <description>Reentrant driver location relationship with lines of block, wavefront curvature, and slow conduction areas during SR pacing with success AF termination.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>LAA + LA Map in AF&#xD;
Identify LAA connections and detect rotors with CartoFinder&#xD;
Electrical cardioversion. Sinus rhythm restoration&#xD;
Pacing from the coronary sinus at 300 and 600ms periods&#xD;
Analyze COHERENT activation maps in sinus rhythm&#xD;
Ablation as suggested by current clinical guidelines and the characteristics of the patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary vein electrical isolation</intervention_name>
    <description>Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy.</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Pulmonary veins ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atrial substrate mapping</intervention_name>
    <description>Electro-anatomical maps will be performed with CARTO navigation system with multi-electrode catheters.</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Electro-anatomical mapping</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include 50 patients. No statistical considerations were made to determine&#xD;
        the sample size of this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persistent atrial fibrillation&#xD;
&#xD;
          -  The patient has signed the informed consent form&#xD;
&#xD;
          -  No LAA previous ablation procedure&#xD;
&#xD;
          -  No valvular disease&#xD;
&#xD;
          -  LVEF ≥ 35% prior to recruitment&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  LVEF &lt; 35 %&#xD;
&#xD;
          -  Hyperthyroidism or hypothyroidism&#xD;
&#xD;
          -  Mental or physical illness incapacitation&#xD;
&#xD;
          -  Planned cardiac procedure&#xD;
&#xD;
          -  Non-controlled hypertension&#xD;
&#xD;
          -  Terminal renal failure or dialysis&#xD;
&#xD;
          -  Class IV of the NYHA&#xD;
&#xD;
          -  Age ≥ 75 years&#xD;
&#xD;
          -  Life expectancy &lt; 2 years&#xD;
&#xD;
          -  Atrioventricular block&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ángel Arenal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gonzalo R Ríos-Muñoz, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angel Arenal, MD, PhD</last_name>
    <phone>0034915868290</phone>
    <email>arenal@secardiologia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gonzalo R Ríos-Muñoz, MSc, PhD</last_name>
    <phone>0034915868290</phone>
    <email>gonzalo.rios.munoz@secardiologia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Arenal, MD, PhD</last_name>
      <phone>0034915868290</phone>
      <email>arenal@secardiologia.es</email>
    </contact>
    <investigator>
      <last_name>Gonzalo R Ríos-Muñoz, MSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Catheter ablation</keyword>
  <keyword>Rotors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

